stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
25.52
0.51
−1.96%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Operating cash flow
Caris Life Sciences,�Inc.'s operating cash flow for fiscal 2025 was $83.2M, compared with −$245.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $83.9M. Caris Life Sciences,�Inc. ranks 32nd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $83.2M | — |
| FY2024 | −$245.2M | — |
| FY2023 | −$276.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$22.2M | — |
| Jun 2026 | $28.5M | (13.38%) |
| Mar 2026 | $32.9M | (26.58%) |
| Dec 2025 | $44.8M | (28.27%) |
| 7 more quarters | Free account |
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $323.9M |
| PTGX Protagonist Therapeutics, Inc. compare | $131.2M |
| CAI Caris Life Sciences,�Inc. | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.9M |
| TWST Twist Bioscience Corporation compare | −$53.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$157.0M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. compare | −$281.1M |
| CYTK Cytokinetics, Incorporated compare | −$572.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement